A peripherally acting Nav1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain

Anesthesia and Analgesia

Volumn 109, Issue 3, 2009, Pages 951-958

  McGowan, Erin ^a   Hoyt, Scott B ^a   Li, Xiaohua ^a   Lyons, Kathryn A ^a   Abbadie, Catherine ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINOCICEPTIVE AGENT; FREUND ADJUVANT; GABAPENTIN; INDOMETACIN; ISOFLURANE; MEXILETINE; N [1 7 CHLORO 1 ISOPROPYL 2 OXO 2,3,4,5 TETRAHYDRO 1H BENZO[B]AZEPIN 3 YLCARBAMOYL 2 (2 FLUOROPHENYL) ETHYL] 4 FLUORO 2 TRIFLUOROMETHYL BENZAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; N ((R) 1 ((R) 7 CHLORO 1 ISOPROPYL 2 OXO 2,3,4,5 TETRAHYDRO 1H BENZO(B)AZEPIN 3 YLCARBAMOYL) 2 (2 FLUOROPHENYL)ETHYL) 4 FLUORO 2 TRIFLUOROMETHYL BENZAMIDE; N-((R)-1-((R)-7-CHLORO-1-ISOPROPYL-2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO(B)AZEPIN-3-YLCARBAMOYL)-2-(2-FLUOROPHENYL)ETHYL)-4-FLUORO-2-TRIFLUOROMETHYL-BENZAMIDE; NA(V)1.7 PROTEIN, RAT; SODIUM CHANNEL;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HYPERALGESIA; INFLAMMATION; MALE; MOTOR COORDINATION; NEUROPATHIC PAIN; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SPINAL NERVE; ANIMAL; CELL LINE; HUMAN; METABOLISM; NERVE DEGENERATION; PAIN; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; BENZAMIDES; CELL LINE; HUMANS; HYPERALGESIA; INFLAMMATION; MALE; NERVE DEGENERATION; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNELS; SPINAL NERVES;

EID: 70149105324     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e3181b01b02     Document Type: Article

References (44)

1. Marban E, Yamagishi T, Tomaselli GF. Structure and function of voltage-gated sodium channels. J Physiol 1998;508:647-57 (Pubitemid 28220721)
2. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000;26:13-25
3. Wall PD, Gutnick M. Properties of afferent nerve impulses originating from a neuroma. Nature 1974;248:740-3
4. Devor M, Janig W, Michaelis M. Modulation of activity in dorsal root ganglion neurons by sympathetic activation in nerveinjured rats. J Neurophysiol 1994;71:38-47 (Pubitemid 24058839)
5. Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, Kallen RG, Mandel G, Meisler MH, Netter YB, Noda M, Tamkun MM, Waxman SG, Wood JN, Catterall WA. Nomenclature of voltage-gated sodium channels. Neuron 2000;28: 365-8
6. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Nav1.7 and human pain disorders. Trends Neurosci 2007;30:555-63 (Pubitemid 350051424)
7. Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 2007;117:3603-9 (Pubitemid 350224065)
8. Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 2005;124:1333-8 (Pubitemid 40847424)
9. Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005;128:1847-54 (Pubitemid 41373656)
10. Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 2005;57:785-8 (Pubitemid 40798615)
11. Fertleman CR, Ferrie CD. What's in a name-familial rectal pain syndrome becomes paroxysmal extreme pain disorder. J Neurol Neurosurg Psychiatry 2006;77:1294-5 (Pubitemid 44654770)
12. Fertleman CR, Baker Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006;52:767-74 (Pubitemid 44828442)
13. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006;444: 894-8 (Pubitemid 46024997)
14. Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE, Meijer IA, Meury L, Mills T, Moody A, Morinville A, Morten J, O'Donnell D, Raynoschek C, Salter H, Rouleau GA, Krupp JJ. A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet 2007;16:2114-21 (Pubitemid 47354894)
15. Hoyt SB, London C, Ok H, Gonzalez E, Duffy JL, Abbadie C, Dean B, Felix JP, Garcia ML, Jochnowitz N, Karanam BV, Li X, Lyons KA, McGowan E, Macintyre DE, Martin WJ, Priest BT, Smith MM, Tschirret-Guth R, Warren VA, Williams BS, Kaczorowski GJ, Parsons WH. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett 2007;17:6172-7 (Pubitemid 47552831)
16. Williams BS, Felix JP, Priest BT, Brochu RM, Dai K, Hoyt SB, London C, Tang YS, Duffy JL, Parsons WH, Kaczorowski GJ, Garcia ML. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry 2007;46:14693-703 (Pubitemid 350276373)
17. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-10 (Pubitemid 13058546)
18. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-63
19. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55-63 (Pubitemid 24238751)
20. Gold MS. Na(+) channel blockers for the treatment of pain: context is everything, almost. Exp Neurol 2008;210:1-6
21. Black JA, Dib-Hajj S, McNabola K, Jeste S, Rizzo MA, Kocsis JD, Waxman SG. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. Brain Res Mol Brain Res 1996;43:117-31 (Pubitemid 27042398)
22. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 1994;72:466-70 (Pubitemid 24233666)
23. Kim CH, Oh Y, Chung JM, Chung K. The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Brain Res Mol Brain Res 2001;95:153-61 (Pubitemid 33000374)
24. Kim CH, Oh Y, Chung JM, Chung K. Changes in three subtypes of tetrodotoxin sensitive sodium channel expression in the axotomized dorsal root ganglion in the rat. Neurosci Lett 2002;323:125-8 (Pubitemid 34310256)
25. Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, Porreca F. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 2002;95:143-52 (Pubitemid 34076786)
26. Gold MS, Weinreich D, Kim CS, Wang R, Treanor J, Porreca F, Lai J. Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J Neurosci 2003;23:158-66 (Pubitemid 36050415)
27. Joshi SK, Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, Zhang XF, Niforatos W, Kage K, Han P, Krafte D, Faltynek C, Sullivan JP, Jarvis MF, Honore P. Involvement of the TTXresistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain 2006;123:75-82 (Pubitemid 43816759)
28. Akopian AN, Souslova V, Engl S, Okuse K, Ogata N, Ure J, Smith A, Kerr BJ, McMahon SB, Boyce S, Hill R, Stanfa LC, Dickenson AH, Wood JN. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999;2:541-8 (Pubitemid 30491235)
29. Kerr BJ, Souslova V, McMahon SB, Wood JN. A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport 2001;12:3077-80 (Pubitemid 32907008)
30. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 2007;104:8520-5 (Pubitemid 47175520)
31. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004;108:237-47 (Pubitemid 38353046)
32. Gould HJ III, Engl JD, Soignier RD, Nolan P, Minor LD, Liu ZP, Levinson SR, Paul D. Ibuprofen blocks changes in Na v 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. J Pain 2004;5:270-80 (Pubitemid 38859681)
33. Nassar MA, Stirling LC, Forlani G, Baker Matthews EA, Dickenson AH, Wood JN. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 2004;101:12706-11 (Pubitemid 39122087)
34. Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol Pain 2005;1:24
35. Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 1998;18:9607-19 (Pubitemid 28543742)
36. Brochu RM, Dick IE, Tarpley JW, McGowan E, Gunner D, Herrington J, Shao PP, Ok D, Li C, Parsons WH, Stump GL, Regan CP, Lynch JJ Jr, Lyons KA, McManus OB, Clark S, Ali Z, Kaczorowski GJ, Martin WJ, Priest BT. Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats. Mol Pharmacol 2006;69:823-32 (Pubitemid 43363857)
37. + currents in dorsal root ganglion neurons. Eur J Pharmacol 2005;510:197-208 (Pubitemid 40349198)
38. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 1992;48:261-8
39. Xiao WH, Bennett GJ. C-fiber spontaneous discharge evoked by chronic inflammation is suppressed by a long-term infusion of lidocaine yielding nanogram per milliliter plasma levels. Pain 2008;137:218-28
40. Morinville A, Fundin B, Meury L, Jureus A, Sandberg K, Krupp J, Ahmad S, O'Donnell D. Distribution of the voltage-gated sodium channel Na(v)1.7 in the rat: expression in the autonomic and endocrine systems. J Comp Neurol 2007;504:680-9 (Pubitemid 350246581)
41. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005;57:397-409
42. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937-47 (Pubitemid 38608473)
43. Janig W. What is the mechanism underlying treatment of pain by systemic application of lidocaine? Pain 2008;137:5-6
44. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995;37:246-53